A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients.
A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients. We summarize the phase III clinical trial of target therapy and inmmunotherapy for glioblastoma and discuss the challenge faced contemporaneously and prospects of targeted drugs and immunotherapy in the future.